Healthcare CRO Services Market in Asia Pacific is expected to register a CAGR of 9% during the forecast period (2019-2025) - KBV Research

16-Apr-2020 | Report Format: Electronic (PDF)

Growth, Trends and Report Highlights

According to a new report Asia Pacific Healthcare CRO Services Market, published by KBV research, the Asia Pacific Healthcare CRO Services Market would witness market growth of 9% CAGR during the forecast period (2019-2025).

The China market dominated the Asia Pacific Cardiovascular Disease Market by Country 2018, and would continue to be a dominant market till 2025. The Japan market is witnessing a CAGR of 10.7% during (2019 - 2025). Additionally, The India market is anticipated to grow at a CAGR of 10.6% during (2019 - 2025).

The Clinical Research Services market dominated the Singapore Healthcare CRO Services Market by Service Type 2018, thereby, achieving a market value of $341.8 million by 2025, growing at a CAGR of 9 % during the forecast period. The Early Phase Development market is experiencing a CAGR of 9.2% during (2019 - 2025). Additionally, The Laboratory Services market would witness CAGR of 11% during (2019 - 2025).

The Pharmaceutical Sector market dominated the South Korea Healthcare CRO Services Market by End User 2018, growing at a CAGR of 8.4 % during the forecast period. The Medical Device Sector market is poised to grow at a CAGR of 10.1% during (2019 - 2025). Additionally, The Services market is expected to witness CAGR of 13% during (2019 - 2025).

Structural Insights: https://www.kbvresearch.com/asia-pacific-healthcare-cro-services-market/

The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the mentioned countries. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of IQVIA Holdings, Inc., Laboratory Corporation of America Holdings (Covance, Inc.), Pharmaceutical Product Development, Inc., Parexel International Corporation (Pamplona Capital Management), Charles River Laboratories International, Inc., ICON PLC, Dassault Systemes SE (Medidata Solutions, Inc.), Syneos Health, Inc., Pharmaron Beijing Co., Ltd., and GVK Biosciences Private Limited.